Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Zealthy Weight Loss Overview Cost: $49 for your first month and $135 per month thereafter Types of weight loss medications: ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Millions of Brits are now eligible for the appetite-suppressing jabs which can come with unpleasant side effects - but NHS rationing means only a tiny fraction will be prescribed them ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.

A systematic review of 26 randomized controlled trials (RCTs) finds that among glucagon-like peptide 1 (GLP-1) receptor agonists and co-agonists on the market or still being investigated, the ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

both of which are glucagon-like peptide-1 (GLP-1) receptor agonists. In a phase 3 trial, tirzepatide demonstrated significant weight loss among participants, with reductions of up to 20.9% in body ...

On the basis of the clinical trial data, patients on Zepbound (tirzepatide) 5mg weekly lost 16.1 kg (35.5 lb) on average after 72 weeks. For Zepbound’s 10mg weekly dose, the average weight loss ...